By HotStockRockets | Monday 18 September 2017
Disclosure: Financial Investigative Media Limited, which is not owned by Tom Winnifrith but by a trust for his dependants, owns shares in companies mentioned in this article. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
This is sad news for sufferers of for Epidermolysis Bullosa (EB) but very good news for we shareholders in Amryt Pharma (AMYT). Overnight last Thursday, the rival, Amicus announced that its Phase 3 asset SD-101 for Epidermolysis Bullosa has failed in Phase 3. The drug failed to meet all co-primary and secondary endpoints, which could suggest that there was minimal/no biological effect.
Filed under:
Friday »
Thursday »
Wednesday »
Tuesday »
Monday »
Sunday »
Saturday »
Friday »
Wednesday »
Tuesday »
Monday »
Sunday »
Saturday »
Friday »
Wednesday »
Tuesday »
Monday »
Sunday »
Saturday »
Friday »
Thursday »
Wednesday »
Tuesday »
Monday »
Sunday »
Saturday »
Friday »
Thursday »
Wednesday »
Time left: 03:52:45